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Abstract 17 
BACKGROUND: Piroxicam (PRX) is a non-steroidal anti-inflammatory drug (NSAID) 18 
commonly used to relieve pain and swelling of conditions like arthritis. PRX has been extensively 19 
detected in seawater, surface, and sewage waters worldwide and therefore its efficient treatment is 20 
an issue of emerging concern. In this work, the sonochemical degradation of PRX was 21 
investigated.  22 
RESULTS: All experiments were conducted at constant ultrasound frequency of 20 kHz while the 23 
following range of experimental conditions was investigated: initial PRX concentration 320–24 
960μg/L, ultrasound power density 20–60 W/L, temperature 20–60 oC, reaction time up to 60 min. 25 
The effect of different water matrices, namely surface water (SW), bottled water (BW), ultrapure 26 
water (UPW) and humic acid (HA) aqueous solution on process efficiency was also explored. It 27 
was found that PRX degradation reached 96% after only 10 min of treatment at the best conditions 28 
(i.e. [PRX]0=320 mg/L, 20
oC, 36 W/L) assayed. Power density could positively affect PRX 29 
degradation. Nevertheless, PRX degradation decreased when its initial concentration and the 30 
temperature of the bulk liquid was increased. PRX degradation was found to decrease, in different 31 
water matrices, in the order: UPW > 5 mg/L HA > BW > 10 mg/L HA >SW. High resolution mass 32 
spectrometry analysis revealed that fourteen transformation by-products (TBPs) were formed and 33 
subsequently degraded during treatment while the PRX degradation pathways were also 34 
elucidated. 35 
CONCLUSION: At the optimal operating conditions assayed, PRX was efficiently degraded after 36 
about 10 min of sonochemical oxidation, thus rendering it a promising technology for the treatment 37 
of xenobiotics 38 
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1. Introduction 41 
Piroxicam (PRX) is a non-steroidal anti-inflammatory drug (NSAID) commonly used to relieve 42 
pain and swelling of conditions like arthritis. NSAIDs, including PRX, have been extensively 43 
detected in seawater, surface, and sewage waters worldwide,1-3 since these are among the most 44 
frequently used drugs (painkillers, antipyretics, treatment of inflammations and prevention of 45 
myocardial infarction). The presence of such drugs, even at low concentrations (from ng/L to 46 
mg/L), can have a significant impact on the aquatic and terrestrial systems, and therefore this is an 47 
issue of emerging concern.4 48 
Excretion (from human and animal medical care) is the major source of water and soil pollution 49 
by drugs. These are excreted as unchanged or metabolites, which after disposal to municipal 50 
sewage systems find their way to the environment.3 Wastewater treatment plants (WWTPs) have 51 
been mainly designed to remove suspended solids and organic content while their effect on the 52 
removal of micropollutants may be, in most cases, negligible.1 Therefore, when drugs enter 53 
conventional biological WWTPs, only a small fraction is removed and residual amounts are 54 
released into the terrestrial and aquatic environment, causing major environmental and health 55 
concerns. Due to inadequacy of current WWTPs to completely remove such contaminants, 56 
additional or alternative processes should be applied to support existing treatment facilities and 57 
increase their efficiency. 58 
Sonochemical oxidation is an advanced oxidation process (AOP), which has gained considerable 59 
attention over the past decades for the treatment of several trace pollutants, including 60 
pharmaceutical substances.5-7 Sonochemical oxidation is based on the in situ generation of 61 
powerful oxidizing agents, such as the hydroxyl radical. These are formed through the cyclic 62 
formation, growth and implosive collapse of bubbles that behave as hot-spot, micro-reactors.8,9 At 63 
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sufficient contact time and proper operating conditions, sonochemical oxidation may mineralize 64 
all organic carbon to CO2, which is the most stable end product of chemical oxidation. The 65 
sonochemical degradation of various NSAIDs, such as ibuprofen,10,11 naproxen,12 and 66 
diclofenac13-16  has been investigated. Nevertheless, to the best of our knowledge, there is no study 67 
on the sonochemical degradation of PRX, a commonly used NSAID. In addition, unlike other 68 
drugs, the advanced oxidation of PRX has been merely explored. Specifically, there is only one 69 
study by Feng et al.,17 who investigated the degradation of three NSAIDs, including PRX by means 70 
of ozone or H2O2/O3 treatment. That study focused on determining the bio-availability of chemical 71 
intermediates formed in ozonated water onto a biofilm-supporting granular activated carbon.  72 
The purpose of this work is to investigate the sonochemical oxidation of PRX, evaluate the effect 73 
of key operating parameters that can determine degradation rates and propose degradation 74 
pathways. Therefore, the following parameters, namely initial PRX concentration, power density, 75 
reaction time, water matrix, and temperature are studied. Transformation by-products are 76 
identified and a potential degradation pathway is proposed.   77 
 78 
2. Materials and methods 79 
2.1 Materials 80 
Piroxicam (PRX) (C15H13N3O4S, CAS no: 36322-90-4) was supplied by Sigma–Aldrich and used 81 
as received. All experiments, unless otherwise stated, were performed in ultrapure water (UPW) 82 
with pH = 6.5 taken from a water purification system (EASYpureRF-Barnstead/Thermolyne, 83 
USA). Two more water matrices were employed for this study. One was a commercially available 84 
bottled water (BW) (pH = 7.5, 0.4 mS/cm conductivity containing 211 mg/L bicarbonate, 10 mg/L 85 
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chloride, 15 mg/L sulfate, 5 mg/L nitrate and 78 mg/L of various metal ions), and the other was 86 
surface water (SW) collected from a stream near the city of Athens, Greece (pH=7.8, 166 mg/L 87 
bicarbonate, 11 mg/ chloride, and 51 mg/L sulfate). Humic acid (HA, CAS number 1415-93-6) 88 
was purchased from Sigma–Aldrich. Sodium chloride (NaCl, CAS no: 7647-14-5) and sodium 89 
bicarbonate (NaHCO3, CAS no: 144-55-8), used as free radical scavengers, were purchased from 90 
Sigma-Aldrich. 91 
 92 
2.2 Ultrasound irradiation 93 
A Branson 450 horn-type digital sonifier operating at a fixed frequency of 20 kHz and a variable 94 
power output up to 450W (nominal) was employed. Sonochemical oxidation took place in a 95 
cylindrical, double-walled, Pyrex vessel, which was open to the atmosphere. Ultrasound irradiation 96 
was emitted through a 1 cm in diameter titanium tip which was positioned in the middle of the 97 
vessel at a distance of 3 cm from the bottom. The working volume was 0.12 L and the actual power 98 
density emitted to the bulk solution was determined calorimetrically and it was found to be 99 
between 20 and 60 W/L. Temperature was kept at 20 oC, unless otherwise stated, by a temperature 100 
control unit. Most experiments were performed in duplicate and mean values, whose standard 101 
deviation never exceeded 5%. Samples of 1.2 mL were periodically taken from the reactor and 102 
analyzed as follows. 103 
 104 
2.3 Chromatographic techniques 105 
High performance liquid chromatography (HPLC: Alliance 2695, Waters) was employed to 106 
monitor the concentration of PRX. Separation was achieved on a Kinetex XB-C18 100A column 107 
7 
 
(2.6 μm, 2.1 mm × 150 mm) and a 0.5 μm inline filter (KrudKatcher Ultra) both purchased from 108 
Phenomenex. The mobile phase consisting of 68:32 water:acetonitrile eluted isocratically at 0.35 109 
mL/min and 45 οC, while the injection volume was 100 μL. Detection was achieved through a 110 
photodiode array detector (Waters 2996 PDA detector, detection λ = 350 nm). The limit of 111 
detection was 3.52 μg/L, and the limit of quantitation was 11.75 μg/L 112 
LC-MS/TOF analysis was carried out on a system, consisted of a Dionex UHPLC Ultimate 3000 113 
connected to a BRUKER micrOTOF Focus II mass spectrometer. Gradient methods were 114 
developed on a Thermo Scientific Acclaim TM RSLC 120 C18 column (protected by a guard from 115 
Waters) thermostated at 30° C, using a mixture of water/1mM ammonium formate and methanol 116 
as mobile phase at a flow rate of 0.3 mL/min. The elution starts with 1% methanol and 117 
progressively increases to 99% (methanol) at 10 min. At 12 min the initial conditions are reached 118 
and retained for 3 min (15 min). The micrOTOF Focus II was operated in both ionization modes 119 
(positive and negative) as follows: dry gas at 8 L/min, nebulizer press at 2.4 bar, dry heater at 200° 120 
C, hexapole RF at 100 Vpp and capillary voltage at 4500 V. Accurate mass measurements provided 121 
by micrOTOF Focus II mass spectrometer and the interpretation of fragments derived from in 122 
source Collision-induced Dissociation (isCID) was used for the structural assignment of 123 
transformation by-products (TBPs). 124 
 125 
3. Results and discussion 126 
3.1 Effect of initial PRX concentration 127 
The effect of initial PRX concentration, ranging from 320 μg/L to 960 μg/L, on its degradation 128 
rate was studied. Figure 1 shows PRX degradation as a function of treatment time at 36 W/L power 129 
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density, and constant temperature of 20 oC. Complete removal is achieved after 25 min of treatment 130 
for 640–960 μg/L PRX and this decreases to almost 10 min when initial PRX concentration is 320 131 
μg/L. Data of Figure 1 are found to fit well a pseudo first-order reaction, which is in agreement 132 
with previous studies on sonochemical degradation of other NSAIDs, such as ibuprofen 18 and 133 
diclofenac 14,15,19. In the inset graph of Figure 1 it is observed that the kinetic rate coefficients, k, 134 
decrease when the initial substrate concentration is increased. For example, rate coefficients are 135 
0.1459 min-1, 0.1695 min-1 and 0.2098 min-1 when the initial PRX concentration is 960 μg/L, 640 136 
μg/L and 320 μg/L, respectively. The fact that rate coefficient changes with varying PRX 137 
concentration implies that the reaction is not true first order although data fitting to first-order 138 
kinetics equation (i.e. Ln [PRX]o/[PRX]=kt) is good.  139 
 140 
Figure 1. 141 
 142 
3.2 Effect of power density 143 
Ultrasound power is a key operating parameter that can substantially affect efficiency of 144 
sonochemical oxidation. Therefore, different power densities, ranging from 20 to 60 W/L, were 145 
applied for the degradation of 640 μg/L PRX and the results are shown in Figure 2. As seen 146 
conversion increases with increasing applied power. Not only this but, as shown in the inset graph 147 
of Figure 2, a nearly linear increase of PRX degradation with power density is observed. 148 
Specifically, reaction rate coefficients are 0.1157 min-1 (r2=0.9688), 0.1695 min-1 (r2=0.9868) and 149 
0.1967 min-1 (r2=0.9921) when power density is 20, 36 and 60 W/L, respectively. This increase of 150 
PRX degradation can be attributed to the fact that, at higher power levels, the transmittance of 151 
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ultrasonic energy into the reactor increases. As a result, a larger number of cavitation bubbles are 152 
formed and the pulsation and collapse of bubbles occur at a faster rate, thus increasing significantly 153 
the concentration of hydroxyl radicals generated, and the subsequent H2O2 production in the liquid 154 
mixture, leading to enhanced organics degradation rates.20-22 Furthermore, an increase in ultrasonic 155 
power contributes to higher mixing intensity due to the turbulence and microstreaming which are 156 
generated during the cavitational microbubble collapse,23 which can also contribute to increased 157 
PRX degradation rates. 158 
 159 
Figure 2.  160 
 161 
3.3 Effect of bulk temperature 162 
Experiments were performed at 20 oC, 40 oC and 60 oC in order to study the effect of temperature 163 
on the degradation of 320 μg/L PRX at 36 W/L power density. Results in Figure 3 show that an 164 
increase in bulk temperature can reduce process efficiency, and therefore total degradation of PRX 165 
is achieved after about 10, 20 and 40 min of sonochemical treatment at 20 oC, 40 oC and 60 oC, 166 
respectively. Temperature of the bulk liquid can affect several parameters such as the vapor 167 
pressure, viscosity, gas solubility and surface tension. Therefore, the negative effect of temperature 168 
on PRX degradation may be explained by the following: the increase in temperature increases the 169 
vapor pressure of the solvent. Consequently, the cavitation bubbles contain more water vapor. 170 
Because of this increased vapor content, the collapse of the cavitation bubbles is less violent, which 171 
is known as the ‘cushioning effect’. This causes a reduction in the collapse temperature and thus a 172 
reduced production of •OH radicals. In addition to this, increased temperatures are likely to favour 173 
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degassing of the liquid phase, thus reducing the number of gas nuclei available for bubble 174 
formation.20,24 175 
 176 
Figure 3.  177 
 178 
3.4 Effect of the water matrix  179 
The complexity of the water matrix is another operating parameter that can affect process 180 
efficiency. To assess its effect, experiments were conducted in surface water (SW), bottled water 181 
(BW), as well as in UPW spiked with humic acid (HA) at two concentrations (5 and 10 mg/L); in 182 
all cases, PRX concentration was 320 μg/L and the power density 36 W/L at 20 οC. Results in 183 
Figure 4 show that there is a decrease in the degradation rate in the presence of HA, BW and SW 184 
compared to that of UPW. This may be attributed to the fact that HA, BW, and SW contain other 185 
organic or inorganic substances that can act as hydroxyl radical scavengers and can therefore 186 
significantly lower the degradation of the target contaminant25. Specifically, PRX degradation is 187 
found to decrease in the order: UPW (0.2098 min-1) > 5 mg/L HA (0.1005 min-1) > BW (0.0819 188 
min-1) > 10 mg/L HA (0.0706 min-1) > SW (0.0646 min-1) with numbers in brackets corresponding 189 
to kinetic rate coefficient. The lower degradation rates in the presence of HA, a model natural 190 
organic matter (NOM), may be due to the much higher concentration of organic carbon in the 191 
solution (5–10 mg/L HA versus 320 μg/L PRX), which competes with the substrate for the 192 
oxidative species26. Moreover, it is observed that increase of the initial HA concentration, from 5 193 
to 10 mg/L, negatively affects PRX degradation, since the amount of the organics competing with 194 
PRX is higher at 10 mg/L than at 5 mg/L HA. PRX degradation in SW, which is the most complex 195 
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matrix studied, since it consists of NOM and several inorganic substances, is found to be lower 196 
than in all other water matrices. Therefore, results indicate that when the complexity of the water 197 
matrix is increased process efficiency is decreased.  198 
 199 
Figure 4. 200 
 201 
The presence of chlorides and bicarbonates in BW and SW partially impedes degradation since 202 
inorganics can scavenge hydroxyl radicals26. This was further demonstrated by performing 203 
experiments in UPW spiked with chlorides, in the form of NaCl, and sodium bicarbonate for 204 
degrading 320 μg/L PRX at 36 W/L power density and 20 οC. As shown in Figure 5, PRX 205 
degradation rate is substantially decreased in the presence of 250-500 mg/L NaCl as well as of 50-206 
250 mg/L BIC. Results from this work are in agreement with previous studies dealing with the 207 
sonochemical degradation of drugs. For example, Xiao et al.11 found that in the presence of 208 
terephthalate (TA), a typical •OH scavenger and dissolved Suwannee river fulvic acid (SRFA) the 209 
degradation rates of ciprofloxacin and ibuprofen are significantly reduced compared to no TA or 210 
SRFA present. Moreover, Gao et al. 22 reported that sulfamethoxazole degradation was inhibited 211 
in the presence of NO3
-1, Cl- and SO4
-2 and the inhibition degree followed the order of NO3
-1,> Cl- 212 
> SO4
-2. 213 
 214 
Figure 5. 215 
 216 
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3.5 Identification of transformation by-products (TBPs) and degradation pathways 217 
Simultaneously with PRX degradation, the formation and subsequent degradation of 14 TBPs was 218 
revealed. Structural assignment was based on high resolution accurate mass measurements in both 219 
positive and negative ionization mode (Tables 1 and 2). Firstly, under negative ionization mode 220 
PRX presents a molecular ion peak [M-H]- at m/z 330.0554 and fragments (isCID MS) at m/z 221 
266.0922 and 210.0224, which correspond to the loss of -SO2 followed intramolecular 222 
rearrangement and loss of pyridinecarboxamide moiety, respectively. The fragment ion at m/z 223 
146.0602 is generated by the loss of -SO2 followed intramolecular rearrangement from the 224 
210.0224 fragment ion. Three TBPs (TBP 9, 10, 12) with molecular ions at m/z 346.0493-225 
346.0506 that differ about 16 amu from the PRX are identified as hydroxylated derivatives. 226 
Pyridine, benzothiazine moieties and N-methyl group can be considered as potential sites of 227 
hydroxylation. TBP 12 shows a fragment at m/z 226.0180 which corresponds to the loss of 228 
pyridinecarboxamide moiety indicating that hydroxylation takes place at the benzothiazine moiety 229 
or N-methyl group. On the other hand, TBP 9 and 10 show close retention times but no diagnostic 230 
fragments. However, the hydroxylation of PRX molecule in the pyridinyl ring and more 231 
specifically at the 5'-position can be proposed for one of the isomeric TBPs since 5'-232 
hydroxypiroxicam is reported as a well-known metabolite of PRX in the literature.28 233 
In addition, two di-hydroxylated TBPs (TBP 6 and 11) are detected on the basis of +32 amu 234 
difference from the PRX molecule. TBP 11 shows a characteristic diagnostic fragment at m/z 235 
210.0224 corresponding to the loss of C6H4N2O3 suggesting that hydroxylation takes place on the 236 
pyridinyl ring. Four isomeric TBPs (TBP 4, 5, 7, 8) with m/z 212.0015-212.0030 and TBP 3 are 237 
proposed as the mono- and di-hydroxylatedbenzothiazine derivatives, respectively. Finally, TBPs 238 
1, 2, 13 and 14 are identified as 1,2-benzisothiazol-3(2H)-one-1,1-dioxide, N-methyl-239 
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benzenesulfonamide, N1-(pyridin-2-yl)oxalamide and N1-methyl-N2-(pyridin-2-yl)oxalamide. 240 
The profiles (peak area vs irradiation time) of the TBPs are shown in Figure 6. The sequence of 241 
the PRX transformation paths can be proposed based on the time within the maximum 242 
concentration of each TBP is observed. Therefore, TBPs 9, 10 and 12 (mono-hydroxy-TBPs) 243 
peaked up at 120 min allows us to consider them as first-stages TBPs. Di-hydroxylated-PRX 244 
derivatives (TBPs 6 and 11) and mono-, di-hydroxylated benzothiazine derivatives (TBPs 4, 5, 7 245 
and 8) peaked up at 180 min can be considered as secondary products. Finally, TBPs 1, 2, 13 and 246 
14 are detected only in samples after 240 min of treatment and at low concentration levels and thus 247 
they can be considered as later stage products. For the sake of comparison with other studies 248 
dealing with the degradation of PRX, TBP 14 and structurally similar TBPs have been also 249 
identified as degradation products of PRX under oxidative and photolytic conditions.29-32 In 250 
addition, the in vivo formation of the metabolic oxidation product 5-hydroxypiroxicam and at least 251 
13 new secondary peaks (without structure identification) after the in vitro study of hydroxyl 252 
radical attack of PRX was reported elsewhere.33 253 
Taking into account the identification and structural assignment of the TBPs, as well as their 254 
evolution profiles, the sonochemical degradation mechanisms of PRX are proposed in Figure 7. 255 
The first steps of degradation start with hydroxyl radical attack on PRX molecule leading to the 256 
formation of hydroxylated, di-hydroxylated derivatives. In parallel, apart from the generation and 257 
attack of hydroxyl radicals, singlet oxygen (1O2) can be also formed in ample amounts 
34 during 258 
the ultrasound treatment. PRX quenches 1O2 with rate constants in the order of 10
8 M−1 s−1 showing 259 
a significant photodegradation efficiency, as reported elsewhere.35 This pathway proceeds by the 260 
addition of singlet oxygen to the enol double bond and the formation of a dioxetane intermediate. 261 
Ring cleavage of this unstable intermediate, leads to its conversion in a carboxylic acid structure, 262 
14 
 
as depicted in Figure 7 29,30,32, which is further transformed to later stages TBPs, such as TBP 1, 2, 263 
13 and 14. The same degradation mechanism was proposed for the photochemical oxidation of 264 
PRX.29,30,32 265 
 266 
4. Conclusions 267 
The aim of this work was to investigate the sonochemical degradation of piroxicam (PRX), a 268 
commonly used non-steroidal anti-inflammatory drug. For this purpose, the effect of key operating 269 
parameters was evaluated. The following parameters, namely initial PRX concentration, 270 
ultrasound power density, temperature, water matrix, and treatment time were studied. 271 
Transformation by-products were identified and a potential degradation pathway was identified. 272 
The main findings  drawn from this study are summarized below. 273 
 An increase of power density leads to enhanced PRX degradation rates, since at high power 274 
densities the amount of hydroxyl radicals generated and the mixing intensity are increased. 275 
 Increasing the temperature of the bulk liquid results in a reduction of sonochemical activity 276 
and this may be attributed to the ‘cushioning’ phenomenon. 277 
 Water matrices containing organic and inorganic radical scavengers can have adverse effect 278 
on degradation kinetics compared to runs in ultrapure water. Also, when the complexity of 279 
the water matrix is increased process efficiency is decreased. 280 
 Sonochemical degradation starts with hydroxyl radical attacking on PRX molecule leading 281 
to the formation of hydroxylated and di-hydroxylated derivatives. At the same time, singlet 282 
oxygen is added to the enol double bond, thus leading to the formation of a dioxetane 283 
15 
 
intermediate, which is consequently converted to a carboxylic acid structure and other later 284 
stages transformation by-products. 285 
In general ultrasound irradiation seems a promising technology with relative high efficiency (i.e 286 
removal of hundreds of μg/L in less than few minutes) for the destruction of micro pollutants. 287 
Further research is needed with particular emphasis at the scale up of the process in order to study 288 
the industrial application of sonochemsitry in environmental protection. 289 
 290 
  291 
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Table 1. 402 
TBP code Rt (min) Deprotonated 
molecular formula 
m/z [Μ-Η]- Δ (ppm) RDBE 
TBP1 4.4 C7H4NO3S 181.9925 -4.0 6.5 
TBP2 4.7 C7H8NO2S 170.0276 3.2 4.5 
TBP3 5.1 C8H6NO5S 227.9972 -1.2 6.5 
TBP4 5.4 C8H6NO4S 212.0030 -3.4 6.5 
TBP5 6.0 C8H6NO4S 212.0021 0.9 6.5 
TBP6* 6.1 C15H12N3O6S 362.0452 0 11.5 
TBP7 6.3 C8H6NO4S 212.0026 -1.2 6.5 
TBP8 6.6 C8H6NO4S 212.0015 4.0 6.5 
TBP9* 6.9 C15H12N3O5S 
C15H12N3O3 
346.0493 
282.0875 
3.0 
3.3 
11.5 
11.5 
TBP10* 7.1 C15H12N3O5S 
C15H12N3O3 
346.0494 
282.0875 
2.7 
3.3 
11.5 
11.5 
PRX 7.2 C15H12N3O4S 
C15H12N3O2 
C9H8NO3S 
C9H8NO 
330.0554 
266.0922 
210.0224 
146.0602 
0 
4.9 
2.9 
6.6 
11.5 
11.5 
6.5 
6.5 
TBP11* 7.6 C15H12N3O6S 
C15H12N3O2 
C9H8NO3S 
C9H8NO 
362.0450 
266.0922 
210.0224 
146.0602 
0.7 
4.9 
2.9 
6.6 
11.5 
11.5 
6.5 
6.5 
TBP12* 8.0 C15H12N3O5S 
C9H8NO4S 
346.0506 
226.0180 
-0.8 
-1.4 
11.5 
6.5 
 403 
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Table 2.  404 
TBP code Rt 
(min) 
Protonated 
molecular formula 
m/z 
[Μ+Η]+ 
Δ (ppm) RDBE 
TBP13 5.8 C7H8N3O2 166.0615 -2.4 5.5 
TBP14 6.4 C8H10N3O2 180.0775 -3.9 5.5 
TBP6* 6.1 C15H14N3O6S 364.0591 1.9 10.5 
TBP9* 6.9 C15H14N3O5S 348.0650 -0.3 10.5 
TBP10* 7.1 C15H14N3O5S 348.0651 -0.7 10.5 
PRX 7.2 C15H14N3O4S 332.0687 3.9 10.5 
TBP11* 7.6 C15H14N3O6S 364.0595 0.8 10.5 
TBP12* 8.0 C15H14N3O5S 348.0650 -0.3 10.5 
 405 
  406 
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Figure 1. Effect of initial PRX concentration on its sonochemical degradation at 36 W/L power 408 
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Figure 6. Formation and degradation kinetics of identified TBPs under ultrasonic radiation. 419 
Figure 7. Sonochemical degradation pathways of PRX. 420 
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